Hepatocellular Carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The main PET tracer currently used in oncology applications, 2-[18F]-fluoro-2-deoxy-D-glucose (FDG), has been shown to be ineffective for imaging HCC since many HCCs do not show differential FDG uptake comparing to the surrounding hepatic tissues. Identification of aggressive liver lesions with rapid growth (proliferation) with PET imaging also proves to be difficult since several thymidine analogs (all substrates of thymidine kinase (TK)) developed for proliferation imaging did not work well in the liver due mainly to glucuronidation, which leads to a high liver background uptake. We propose to investigate a newly developed tracer, 1-(2'-deoxy- 2'-[18F]-fluoro-?-D-arabinofuranosyl)cytosine ([18F]-FAC, a substrate more specific for deoxycytidine kinase (dCK) than for TK), which displays a lower liver background uptake. A modifier, tetrahydrouridine (THU, an inhibitor of cytidine deaminase (CDA)), will be added to suppress enzymatic activity of hepatic CDA and maintain FAC activity in the liver. We plan to establish this [18F]-FAC and THU combination for PET imaging of proliferation in HCC based on encouraging preliminary pre-clinical results and clinical biodistribution studies. Our central hypothesis is that FAC uptak is correlated with dCK-dependent proliferation in HCC; and [18F]-FAC-PET (THU) can be used to identify aggressive HCC and to predict response to dCK-dependent treatment. We will test this hypothesis via the following Specific Aims.
Aim 1 : To confirm the mechanism of [18F]-FAC uptake in HCC with a clinically relevant woodchuck model of HCC;
Aim 2 : To validate [18F]-FAC-PET (THU) uptake in patients with HCC;
Aim 3 : To explore the utility of [18F]-FAC-PET (THU) as a companion imaging biomarker for predicting the response to novel dCK-dependent treatment such as the new therapeutic combination of THU-decitabine.
Our study investigates a small molecule radio-tracer FAC along with a modifier THU for PET imaging of up-regulated proliferation in hepatocellular carcinoma (HCC), which is increasing rapidly in frequency in United States. We will establish THU-FAC as a new PET tracer for imaging proliferation in HCC to help identify aggressive liver cancer that requires clinical attention, and to help predict treatment response.
| Zhu, Ziqi; Chung, Yoon-Mi; Sergeeva, Olga et al. (2018) Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging. J Biol Chem 293:17829-17837 |
| Enane, Francis O; Shuen, Wai Ho; Gu, Xiaorong et al. (2017) GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. J Clin Invest 127:3527-3542 |
| Lee, Zhenghong (2016) [18F]-choline PET/CT as an imaging biomarker for primary liver cancers. Transl Cancer Res 5:S1489-S1492 |
| Lee, Zhenghong; Luo, Guangbin (2014) Issues pertaining to PET imaging of liver cancer. J Fasting Health 2:62-64 |
| Ebrahem, Quteba; Mahfouz, Reda Z; Ng, Kwok Peng et al. (2012) High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget 3:1137-45 |
